Standard BioTools (LAB) AI Stock Analysis

• Market Cap: $410.21M
• Dividend Yield: N/A
• Average Volume (3M): 1.34M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.29
• Revenue Growth: 33.86%
• EPS Growth: 64.34%
• Country: US
• Employees: 814
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.07
• Shares Outstanding: 379,822,270
• 10 Day Avg. Volume: 1,429,882
• 30 Day Avg. Volume: 1,339,661
• PEG Ratio: -0.02
• Price to Book (P/B): 0.80
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.68
• Enterprise Value/Market Cap: 0.66
• Enterprise Value/Revenue: 0.46
• Enterprise Value/Gross Profit: 3.24
• Enterprise Value/Ebitda: -0.62
• 1Y Price Target: $2.50
• Price Target Upside: 152.53% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 49 Neutral
• Price Target: $1.00 ▲(1.01%Upside)

The company's overall stock score reflects significant financial challenges and weak technical indicators. Financial performance is the most influential factor, highlighting ongoing profitability issues and cash flow concerns. While strategic initiatives and partnerships offer potential, they have not yet mitigated current financial and operational challenges.

Positive Factors

Earnings

LAB reported 1Q revenue slightly better than consensus estimates, which is a good result in light of ongoing macro pressures and share weakness.

Operational Performance

Cost and operational initiatives continue to bear fruit with an adjusted operating loss improving by about 45% year over year despite a tough backdrop.

Product Development

There are signs of improvement on the horizon with positive customer trends, strengthening sales funnel, and momentum with SomaScan.

Negative Factors

Management Changes

The CFO departure (personal reasons) is a negative surprise though mgmt is steadfast key drivers (synergies, ILMN partnership) are unchanged.

Market Conditions

Consumables and services were both light due to US academic customer softness and declining field services revenue.

Revenue Guidance

LAB posted its preannounced 4Q24 with disappointing initial 2025 revenue guidance of $165M-$175M vs. consensus of $186.9M.

Standard BioTools Business Overview & Revenue Model

Company Description

Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

How the Company Makes Money

Standard BioTools generates revenue primarily through the sale of its analytical instruments and consumables. The company offers a range of products that cater to different aspects of biological research, including genomics and proteomics. Revenue streams include direct sales to research institutions and laboratories, as well as partnerships and collaborations with pharmaceutical companies that utilize its technology for drug discovery and development. Additionally, the company may earn from service agreements, training, and customer support related to its products. Significant factors contributing to its earnings include the growing demand for advanced research tools in the life sciences sector and its ability to innovate and create technologies that address emerging research needs.

Standard BioTools Financial Statement Overview

Summary

Standard BioTools faces significant financial challenges with consistent net losses and declining revenue. While balance sheet improvements exist, such as increased equity, the company's poor cash flow generation and persistent operating losses pose substantial risks to financial sustainability.

Income Statement

The company has experienced a decline in revenue over recent years, with Total Revenue decreasing from $138.1 million in 2020 to $106.3 million in 2023. Gross Profit Margin remains stable but negative Net Profit Margins indicate continuous losses. EBIT and EBITDA margins are negative, mirroring sustained operating losses. The revenue growth is negative, reflecting challenges in the company's ability to expand its market presence.

Balance Sheet

The balance sheet shows a moderate level of stability with a strong equity base as Stockholders' Equity increased significantly by 2023. The Debt-to-Equity Ratio decreased, indicating lower financial leverage. The Equity Ratio has improved, suggesting a stronger asset base relative to equity. However, persistent losses impact overall financial health.

Cash Flow

The company's cash flow situation is concerning, with negative Free Cash Flow and Operating Cash Flow to Net Income ratios. Free Cash Flow has declined significantly, indicating poor cash generation capabilities. The Operating Cash Flow has been consistently negative, highlighting operational inefficiencies.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
174.43M	106.34M	97.95M	130.58M	138.14M
	Gross Profit
84.26M	50.45M	37.05M	69.37M	83.33M
	EBIT
-175.24M	-76.60M	-116.20M	-67.46M	-51.04M
	EBITDA
-118.14M	-54.46M	-173.57M	-43.77M	-34.60M
	Net Income Common Stockholders
-138.88M	-74.66M	-190.10M	-59.24M	-53.02M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
292.87M	114.89M	165.78M	28.45M	68.52M
	Total Assets
612.34M	323.07M	390.31M	275.21M	324.76M
	Total Debt
33.00M	98.21M	102.66M	111.65M	95.38M
	Net Debt
-133.73M	46.51M	21.35M	83.20M	26.86M
	Total Liabilities
140.62M	159.87M	471.78M	180.62M	185.71M
	Stockholders Equity
471.72M	163.20M	-81.47M	94.60M	139.05M
Cash Flow		Free Cash Flow
-151.81M	-46.12M	-93.19M	-57.33M	-28.13M
	Operating Cash Flow
-143.45M	-43.29M	-89.37M	-44.06M	-15.42M
	Investing Cash Flow
363.17M	20.24M	-88.13M	-11.95M	39.98M
	Financing Cash Flow
-102.62M	-6.81M	230.76M	15.96M	20.86M

Standard BioTools Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.99
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LAB, the sentiment is Negative. The current price of 0.99 is below the 20-day moving average (MA) of 1.05, below the 50-day MA of 1.11, and below the 200-day MA of 1.57, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 43.45 is Neutral, neither overbought nor oversold. The STOCH value of 70.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LAB.

Standard BioTools Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CSTL	65 Neutral	$491.41M	30.59	-1.20%	―	38.43%	86.19%
FLGT	59 Neutral	$648.14M	―	-3.61%	―	1.71%	76.00%
PSNL	57 Neutral	$454.87M	―	-51.25%	―	15.57%	31.82%
Sector *	54 Neutral	$5.28B	3.29	-45.38%	2.80%	16.77%	-0.08%
OPK	52 Neutral	$1.09B	―	-3.04%	―	-13.79%	82.82%
MYGN	51 Neutral	$487.62M	―	-13.84%	―	12.15%	61.33%
LAB	49 Neutral	$410.21M	―	-25.73%	―	33.86%	64.34%

Standard BioTools Corporate Events

Standard BioTools Q1 2025 Financial Results Overview

Standard BioTools reported its financial results for the first quarter of 2025, showing a revenue of $40.8 million, a 10% decrease from the previous year. Despite the revenue decline, the company achieved a 45% reduction in operating loss and a 29% improvement in adjusted EBITDA, attributed to cost reductions and productivity gains. The company maintains a strong balance sheet with $261 million in cash and no material debt. The strategic focus on proteomics and the upcoming launch of a new NGS-based product are expected to drive future growth.